ATXN3 — Ataxin-3

ATXN3 — Ataxin-3

Introduction

ATXN3 (Ataxin-3) is a deubiquitinating enzyme (DUB) of the Josephin family that plays critical roles in protein quality control, transcriptional regulation, and DNA repair. The gene is located on chromosome 14q32.12 and contains a CAG trinucleotide repeat in the coding region that undergoes pathological expansion in Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD). This is the most common dominantly inherited ataxia worldwide, accounting for approximately 20-30% of all dominant cerebellar ataxias["@lima2022"].

ATXN3 — Ataxin-3

Introduction

ATXN3 (Ataxin-3) is a deubiquitinating enzyme (DUB) of the Josephin family that plays critical roles in protein quality control, transcriptional regulation, and DNA repair. The gene is located on chromosome 14q32.12 and contains a CAG trinucleotide repeat in the coding region that undergoes pathological expansion in Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD). This is the most common dominantly inherited ataxia worldwide, accounting for approximately 20-30% of all dominant cerebellar ataxias["@lima2022"].

The normal ATXN3 protein functions as a cysteine protease that cleaves ubiquitin chains from substrate proteins, regulating their degradation through the ubiquitin-proteasome system (UPS)[@burns2020]. Additionally, ATXN3 participates in transcriptional regulation, DNA repair pathways, and autophagy—a cellular process critical for clearing misfolded proteins and damaged organelles["@liu2021"].

The pathogenic expansion of the polyglutamine (polyQ) tract in ATXN3 leads to protein misfolding, aggregation, and neurotoxicity. Expanded ATXN3 forms insoluble aggregates that accumulate in neurons throughout the cerebellum, brainstem, and spinal cord, driving progressive neurodegeneration["@matos2019"].

Gene Overview

<div class="infobox infobox-gene">
<div class="infobox-header">ATXN3 Gene</div>
<div class="infobox-row">
<div class="infobox-label">Gene Symbol</div>
<div class="infobox-value">ATXN3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Ataxin-3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">14q32.12</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/4267" target="_blank">4267</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/607047" target="_blank">607047</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000118004</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/P54252" target="_blank">P54252</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">[Spinocerebellar Ataxia Type 3](/diseases/spinocerebellar-ataxia-type-3), [Machado-Joseph Disease](/diseases/machado-joseph-disease)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal Dominant</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Class</div>
<div class="infobox-value">Deubiquitinating enzyme, Josephin domain protease</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Transcript Length</div>
<div class="infobox-value">~3.3 kb</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Length</div>
<div class="infobox-value">364 amino acids (wild-type)</div>
</div>
</div>

Protein Structure and Function

Domain Architecture

ATXN3 contains several functionally distinct domains[@burns2020][@winborn2018]:

| Domain | Position | Function |
|--------|----------|----------|
| Josephin domain | N-terminus (1-182 aa) | Catalytic DUB activity with Cys-His-Asp triad |
| UIM 1 | Middle region | Ubiquitin binding |
| UIM 2 | Middle region | Ubiquitin binding |
| UIM 3 | Middle region | Ubiquitin binding |
| PolyQ tract | Variable (13-36 normal, 51-86 pathogenic) | Regulatory; undergoes pathological expansion |
| C-terminal region | C-terminus | Protein-protein interactions |

The Josephin domain contains the catalytic triad (Cys178, Asp180, His183) essential for deubiquitinating activity. This domain adopts achpin-fold structure typical of the USP family of DUBs[@burns2020]. The three ubiquitin-interacting motifs (UIMs) facilitate substrate recognition and chain specificity. The polyQ tract, located between UIM2 and UIM3, is the site of pathogenic expansion that drives disease.

Normal Cellular Functions

Under physiological conditions, ATXN3 performs several critical cellular functions:

1. Protein Quality Control
ATXN3 removes ubiquitin chains from misfolded or damaged proteins, regulating their degradation through the proteasome. It shows specificity for both K48 (proteasome-targeted) and K63 (non-degradative) ubiquitin linkages[@matos2019]. This activity is crucial for maintaining cellular proteostasis, particularly in neurons with high metabolic demands.

2. Transcriptional Regulation
ATXN3 interacts with multiple transcription factors and co-regulators, including:

• p53: Modulates p53 transcriptional activity and stability
• HIF-1α: Regulates hypoxia-inducible factor signaling
• Methyl CpG binding protein (MBD): Associates with transcriptional complexes
• Nuclear receptor co-repressors: Modulates steroid hormone receptor activity

3. DNA Repair
ATXN3 associates with DNA repair complexes and participates in the DNA damage response. It has been shown to interact with RAD9, RAD1, and HUS1 components of the 9-1-1 checkpoint complex, suggesting a role in checkpoint activation and DNA repair[@schmidt2019].

4. Autophagy Regulation
Through interaction with p62/SQSTM1, ATXN3 regulates selective autophagy—a process critical for clearing protein aggregates and damaged organelles. ATXN3 deubiquitinates p62, modulating its ability to deliver cargo to autophagosomes[@liu2021].

5. Mitochondrial Quality Control
Recent studies demonstrate ATXN3 involvement in mitophagy—the selective autophagy of mitochondria. This function may be particularly relevant to the neurodegeneration observed in SCA3[@torresodio2021].

Expression Pattern

ATXN3 is ubiquitously expressed with highest levels in the central nervous system. In the brain, expression is particularly high in:

• Cerebellar Purkinje cells
• Cerebellar granule cells
• Brainstem neurons (pontine nuclei, inferior olivary nucleus)
• Spinal cord motor neurons
• Dorsal root ganglion neurons
• Substantia nigra dopaminergic neurons

Disease Associations

Spinocerebellar Ataxia Type 3 (SCA3)

SCA3, also known as Machado-Joseph Disease, is the most common dominant ataxia globally and demonstrates remarkable phenotypic variability[@jardim2001][@lima2022].

Genetics

| Parameter | Normal | Intermediate | Pathogenic |
|-----------|--------|--------------|------------|
| CAG repeat count | 12-44 | 45-59 | 60-87 |
| Penetrance | N/A | Incomplete | Complete by age 60 |

The disease shows anticipation, with earlier onset in successive generations due to intergenerational instability of the CAG repeat, particularly during paternal transmission. Reduced penetrance is observed in individuals with 45-59 repeats[@sequeiros2022].

Pathogenesis

The pathological expansion of the polyQ tract in ATXN3 leads to neurotoxicity through multiple mechanisms[@matos2019][@torresodio2021]:

| Mechanism | Description |
|-----------|-------------|
| Protein misfolding | Expanded polyQ tract adopts abnormal conformations |
| Aggregate formation | Mutant ATXN3 forms insoluble, protease-resistant aggregates |
| Loss of normal function | Decreased DUB activity impairs protein quality control |
| Gain of toxic function | Aggregates sequester essential proteins and organelles |
| Transcriptional dysregulation | Sequestration of transcription factors disrupts gene expression |
| Mitochondrial dysfunction | Impaired energy metabolism and increased oxidative stress |
| Autophagy impairment | Lysosomal clearance defects accumulate |
| Neuroinflammation | Glial activation and cytokine release |

Clinical Features

SCA3 demonstrates significant phenotypic variability, but core features include[@jardim2001][@lima2022]:

Cerebellar Ataxia (present in 100% of patients)

• Gait ataxia: progressive unsteadiness, frequent falls
• Limb ataxia: dysmetria, dysdiadochokinesia
• Truncal ataxia: inability to sit or stand without support
• Dysarthria: scanning speech, difficulty with articulation

• Ophthalmoplegia: horizontal and vertical gaze limitations
• Nystagmus: involuntary eye movements
• Facial fasciculations
• Dysphagia: swallowing difficulties

• Parkinsonism: bradykinesia, rigidity (particularly in early-onset cases)
• Dystonia: involuntary muscle contractions
• Chorea: involuntary movements (less common)

• Reduced deep tendon reflexes
• Distal muscle weakness
• Sensory abnormalities

• Cognitive impairment (later stages): executive dysfunction, memory deficits
• Psychiatric symptoms: depression, anxiety
• Urinary urgency/incontinence

Phenotypic Subtypes

SCA3 patients can be broadly categorized into three subtypes:

Animal Models

Multiple animal models have been developed to study SCA3 pathogenesis and test therapeutic interventions[@goti2004][@silvafernandes2010]:

Transgenic Mouse Models

• ATXN3-84Q transgenic mice: Express human ATXN3 with pathogenic expansion
• ATXN3-70Q knock-in mice: Endogenous expression with expanded CAG repeat
• Conditional models: Enable temporal control of mutant expression

Phenotypic Features in Models

• Progressive motor coordination deficits
• Progressive weight loss
• ATXN3-positive aggregate formation
• Cerebellar and brainstem neurodegeneration
• Gliosis and neuroinflammation

Therapeutic Testing Platforms

• AAV-mediated RNAi delivery
• Antisense oligonucleotide (ASO) approaches
• Small molecule aggregation inhibitors
• Gene editing with CRISPR/Cas9

Therapeutic Approaches

Gene-Silencing Therapies

Antisense Oligonucleotides (ASOs)
ASOs reduce mutant ATXN3 expression by targeting RNA for degradation. Preclinical studies in mouse models showed significant reduction in ATXN3 aggregates and improved motor function[@miller2020]. ASOs can be delivered via intrathecal administration, directly targeting the CNS.

RNA Interference (RNAi)
AAV-mediated RNAi approaches have demonstrated efficacy in preclinical models. Vectors targeting ATXN3 mRNA reduce protein expression and aggregate formation[@rüberg2023].

Gene Editing
CRISPR-based approaches offer potential for directly correcting the CAG expansion. While still in early development, CRISPR technologies could provide durable therapeutic benefit.

Small Molecule Approaches

DUB Modulators
Modulating ATXN3's deubiquitinating activity may restore proteostasis. However, developing selective inhibitors is challenging due to the enzyme's structural similarity to other DUBs.

Aggregation Inhibitors
Compounds that prevent or disperse ATXN3 aggregates are under investigation. These include:

• Bimolecular stabilizers
• Autophagy inducers
• Proteasome enhancers

• Dopaminergic agents: For parkinsonian features (levodopa, dopamine agonists)
• Muscle relaxants: For spasticity (baclofen, tizanidine)
• Anticonvulsants: For seizure control
• Physical therapy: Maintain functional mobility
• Occupational therapy: Optimize daily living skills

Clinical Trials

Several clinical trials are ongoing or recently completed:

| Trial | Phase | Intervention | Status |
|-------|-------|--------------|--------|
| ASO therapy for SCA3 | Phase 1/2 | ASO drug | Recruiting |
| AAV gene therapy | Preclinical | AAV-shRNA | IND-enabling |

Biomarkers

Clinical and neurophysiological biomarkers under development include[@popa2021]:

• Transcranial magnetic stimulation: Measure corticospinal excitability
• Quantitative motor assessments: Objective measures of ataxia severity
• Serum neurofilament light chain: Biomarker of neurodegeneration
• Neuroimaging: MRI volumetry of cerebellum and brainstem

Relationship to Other Neurodegenerative Diseases

ATXN3 shares mechanistic features with other polyglutamine diseases including:

• Huntington's disease (HTT)
• Spinocerebellar ataxia type 1 (ATXN1)
• Spinocerebellar ataxia type 2 (ATXN2)
• Spinocerebellar ataxia type 7 (ATXN7)
• Spinal bulbar muscular atrophy (AR)

• PolyQ-mediated aggregation
• Transcriptional dysregulation
• Mitochondrial dysfunction
• Proteostasis impairment
• [Neuroinflammation](/mechanisms/neuroinflammation)

Current Research Directions

Key research areas include[@blake2023][@costa2024]:

Animal Model Resources

• [Jackson Laboratory: SCA3 Mouse Models](https://www.jax.org/) — Available mouse strains
• [Allen Mouse Brain Atlas: Atxn3](https://mouse.brain-map.org/gene/show?gene_id=100922575) — Expression patterns

External Links

• [NCBI Gene: ATXN3](https://www.ncbi.nlm.nih.gov/gene/4267)
• [UniProt: ATXN3 (P54252)](https://www.uniprot.org/uniprot/P54252)
• [OMIM: 607047](https://www.omim.org/entry/607047)
• [ClinicalTrials.gov: SCA3](https://clinicaltrials.gov/search?cond=SCA3)
• [National Ataxia Foundation](https://ataxia.org/)

See Also

• [Spinocerebellar Ataxia Type 3](/diseases/spinocerebellar-ataxia-type-3)
• [Machado-Joseph Disease](/diseases/machado-joseph-disease)
• [Polyglutamine Diseases](/mechanisms/polyglutamine-diseases)
• [Protein Quality Control](/mechanisms/protein-quality-control)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Deubiquitinating Enzymes](/mechanisms/deubiquitinating-enzymes)
• [Ataxin-3 Protein](/proteins/ataxin-3-protein)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ATXN3 — Ataxin-3 discovered through SciDEX knowledge graph analysis: